Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

Paul G. Corn, MD, PhD
Published: Monday, May 15, 2017



Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

While impressive data have not been reported thus far, researchers still believe that checkpoint inhibitors hold great promise in treating castration-resistant prostate cancer, Corn explains. Although phase III studies were found to be statistically negative, it is clear that a subset of patients does benefit, at least with the use of ipilimumab (Yervoy).

A combination of these drugs may be required. Corn says these checkpoint inhibitors will prove to be an incredibly important avenue of research.
SELECTED
LANGUAGE


Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

While impressive data have not been reported thus far, researchers still believe that checkpoint inhibitors hold great promise in treating castration-resistant prostate cancer, Corn explains. Although phase III studies were found to be statistically negative, it is clear that a subset of patients does benefit, at least with the use of ipilimumab (Yervoy).

A combination of these drugs may be required. Corn says these checkpoint inhibitors will prove to be an incredibly important avenue of research.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x